Generated by AI
PROCEPT BioRobotics Corp. is a commercial-stage surgical robotics company focused on urology. The company develops, manufactures, and sells the AquaBeam Robotic System and the HYDROS Robotic System, both designed for image-guided, minimally invasive urologic procedures. Its core offering is Aquablation therapy, a robotic treatment approach used primarily for benign prostatic hyperplasia and related lower urinary tract symptoms. PROCEPT BioRobotics also supports its systems with consumables, service, and clinical workflow tools that help hospitals and urology practices deliver precise, patient-specific care. The company serves healthcare providers in the United States and selected international markets, positioning itself within the medical device and surgical robotics segments of the healthcare industry.
Website150 Baytech Drive
San Jose, CA, 95134
United States
The latest articles about PRCT.
Tipranks Press Release.
PROCEPT BioRobotics (PRCT) is back in focus after reporting third quarter 2026 results that paired 18% year-over-year revenue growth with a wider net loss, while management held firm on full year guidance. Investors have reacted cautiously to the latest update, with the 1-day share price return declining 6.4% to leave PROCEPT BioRobotics at US$20.27. That move sits against a 30-day share price gain of 15.8%, a year-to-date share price decline of 34.1%, and a 1-year total shareholder return...
Summary of Oct 15's posts. Generated by AI.
No summary yet.
Summary of Oct 28's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
Investors talking about PRCT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.